학술논문

Transcriptomic FHITlow/pHER2(high) signature as a predictive factor of outcome and immunotherapy response in non-small cell lung cancer
Document Type
Journal
Source
FRONTIERS IN IMMUNOLOGY; DEC 5 2022, 13 p1058531 11p.
Subject
Language
English
ISSN
16643224